Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N
FDMT.OQ - 4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc at TD Cowen Healthcare Conference
Mar 03, 2026 / 03:30PM GMT
=====================
Presentation
--------------------------------------------------------------------------------
Unidentified Company Representative [1]
--------------------------------------------------------------------------------
Good morning, everyone. I appreciate the time to share with you, an overview of 4D Molecular Therapeutics. So we'll walk through today, how 4DMT we believe is well positioned to redefine genetic medicines for millions of patients worldwide. I remind you here we may be making forward-looking statements.
So at 4DMT, our goal is to redefine genetic medicines by developing durable, disease-targeted therapeutics for large market diseases. Our lead product, which we'll spend most of the time discussing today, is 4D-150. 4D-150 is a Phase 3 asset currently being studied in Phase 3 for [wet AMD], and I'll share more around our development plans, notably our plans to initiate a trial
Trustpilot
